Seizure discharges induced by the combination of A new quinolinecarboxylic acid antimicrobial drugs and non-steroidal anti-inflammatory drugs

CHEMOTHERAPY

Volumn 36, Issue , 1988, Pages 300-324

  Morikawa, Kohji ^b   Nagata, Osamu ^b   Hashimoto, Shigeki ^b   Yamada, Takehisa ^b   Kubo, Shinji ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b Abbott Japan Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLSALICYLIC ACID; BICUCULLINE; DIAZEPAM; DICLOFENAC; ENOXACIN; FENBUFEN; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LOMEFLOXACIN; MUSCIMOL; NAPROXEN; NEW DRUG; NORFLOXACIN; OFLOXACIN;

ANIMAL EXPERIMENT; CAT; MOUSE; NONHUMAN; RAT; SEIZURE;

EID: 85004443735     PISSN: 00093165     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1953.36.Supplement2-Base_300     Document Type: Article

References (23)

1. Cinoxacin (1). Chemotherapy 28: 530~549, 1980.
2. Wijnands, W. J. A.; C. L. A. van Herwaarden & T. B. Vree: Enoxacin raises plasma theophylline concentrations. The Lancet July 14: 108~109, 1984.
3. Maesen, F. P. V.; J. P. Teengs, C. Baur & B. I. Davies: Quinolanes and raised plasma concentrations of theophylline. The Lancet Sept. 1: 530, 1984.
4. Simpson, K. J. & M. J. Brodie: Convulsions related to enoxacin. The Lancet July 20: 161, 1985.
5. 16: 44-56, 1964.
6. Chiccarelli, F. S.; H. J. Eisner & G. E. Van Lear: Disposition and metabolism of fenbufen in several laboratory animals. Arzneim.-Forsch. 30: 707~715, 1980.
7. Fleitman, J. S. S. G. Schulman & J. H. Perrin: High-performance liquid chromatography assay for fenbufen and two serum metabolites. J. Chromatogr. 228: 372~376, 1982.
8. NY-198 III-HPLC. Chemotherapy 36 (S-2) 144~150, 1988.
9. MÖHler, H. & T. Okada: Benzodiazepine receptor: Demonstration in the central nervous system. Science 198: 849~851, 1977.
10. Zukin, S. R.; A. B. Young & S. H. Snyder: Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc. Nat. Acad. Sci. USA 71: 4802~4807, 1974.
11. NY-198-in vitro in vivo. Chemotherapy 36 (S-2): 99~111, 1988.
12. NY-198 (1). Chemotherapy 36 (S-2) 1265~283, 1988.
13. Cuisinaud, G.; J. Legheand, G. Llorca, C. BelkaHia, E. Lejeune & J. Sassard: Pharmacokinetics of fenbufen in man. Eur. J. Clin. Pharmacol. 16: 59~61, 1979.
14. 2: 37~53, 1980.
15. J. A. Wada: “kindling” preparation: 27: 257~273, 1975.
16. Wood, J. D.: The role of γ-aminobutyric acid in the mechanism of seizures. Prog. Neurobiol. 5: 77~95, 1975.
17. GABA. 5: 887-896, 1983.
18. Olsen, R. W.: GABA-benzodiazepine-barbiturate receptor interactions. J. Neurochem. 37: 1~13, 1981.
19. Tsuji, A.; H. Sato, Y. Kume, I. Tamai, E. Okezaici, O. Nagata & H. Kato: Inhibitory effects of quinolone antibacterial agents on γ-aminobutyric acid binding to receptive sites in rat brain. Antimicrob. Agents Chemother. in press.
20. Iadarola, M. J. & K. Gale: Cellular compartments of GABA in brain and their relationship to anticonvulsant activity. Mol. Cell. Biochem. 39: 305~330, 1981.
21. Iadarola, M. J. K. Gale: Substantia nigra: Site of anticonvulsant activity mediated by yaminobutyric acid. Science 218: 1237~1240, 1982.
22. Mcnamara, J. O.; L. C. Rigsbee & M. T. Galloway: Evidence that substantia nigra is crucial to neural network of kindled seizures. Eur. J. Pharmacol. 86: 485~486, 1983.
23. Czuczwar, S. J.; B. Chmielewska, W. A. Turski & Z. Kleinrok: Differential effects of baclofen, γ-hydroxybutyric acid and muscimol on the protective action of phenobarbital and diphenylhydantoin against maximal electroshock-induced seizures in mice. Neuropharmacology 23: 159~163, 1984.